Biocad — Biomedical Watch V2

Traitements5programmes

Essais2liés

Publications4liées

SourceDBlocale

Traitements

5

Molécule	Indication / population	Phase	Objectif	Pays	Résultat
BCD-063The objective of the clinical study of the medicinal product for medical use: to compare efficacy and safety of the generic drug BCD-063 and Copaxone®-Teva in patients with relapsing-remitting multiple sclerosis. Period of the clinical study of the medicinal product for medical use: from June 10, 2013 to March 23, 2016. Number of patients, involved into the study of the medicinal product for medical use: 158 patients.	SEP	Phase 3	Neuroprotection		À vérifier
BCD-281The aim of this study is to compare the efficacy, safety profile, pharmacokinetics, pharmacodynamics, and immunogenicity of BCD-281 and the reference drug in subjects with relapsing multiple sclerosis.	SEP	Phase 3	À vérifier	Russia	À vérifier
Copaxone-TevaThe objective of the clinical study of the medicinal product for medical use: to compare efficacy and safety of the generic drug BCD-063 and Copaxone®-Teva in patients with relapsing-remitting multiple sclerosis. Period of the clinical study of the medicinal product for medical use: from June 10, 2013 to March 23, 2016. Number of patients, involved into the study of the medicinal product for medical use: 158 patients.	SEP	Phase 3	Neuroprotection		À vérifier
BCD-063The objective of the clinical study of the medicinal product for medical use: to compare efficacy and safety of the generic drug BCD-063 and Copaxone®-Teva in patients with relapsing-remitting multiple sclerosis. Period of the clinical study of the medicinal product for medical use: from June 10, 2013 to March 23, 2016. Number of patients, involved into the study of the medicinal product for medical use: 158 patients.	SEP	Phase 3	Neuroprotection		À vérifier
BCD-281The aim of this study is to compare the efficacy, safety profile, pharmacokinetics, pharmacodynamics, and immunogenicity of BCD-281 and the reference drug in subjects with relapsing multiple sclerosis.	SEP	Phase 3	À vérifier	Russia	À vérifier

Essais cliniques

2

Molécule	Indication / population	Phase	NCT	Titre	Statut
BCD-281	SEP	Phase 3	NCT07321093	MUSCAT — A Study of the Efficacy and Safety of BCD-281 in Patients With Relapsing-Remitting Multiple Sclerosis	RECRUITING
BCD-063	SEP	Phase 3	NCT02753088	Efficacy and Safety of BCD-063 and Copaxone-Teva in Patients With Relapsing-Remitting Multiple Sclerosis	COMPLETED

Publications

4

Molécule	Indication / population	Titre	Journal	Date
Copaxone-Teva		Higher satisfaction and adherence with glatiramer acetate 40 mg/mL TIW vs 20 mg/mL QD in RRMS.	Multiple sclerosis and related disorders
Copaxone-Teva		Physicochemical and Biological Examination of Two Glatiramer Acetate Products.	Biomedicines
Copaxone-Teva		The influence of glatiramer acetate on Th17-immune response in multiple sclerosis.	PloS one
BCD-063		[Comparative, placebo-controlled clinical study of efficacy and safety of glatiramer acetate 20 mg in patients with relapsing-remitting multiple sclerosis: results of the first year of the study].	Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova